{"title":"Le premier et unique agoniste des récepteurs du GIP/GLP-1 pour le traitement du diabète de type 2 [2]","authors":"None Eli Lilly Suisse S.A.","doi":"10.4414/fms.2023.09513","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":30140,"journal":{"name":"Swiss Medical Forum Forum Medical Suisse","volume":"26 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss Medical Forum Forum Medical Suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4414/fms.2023.09513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
